There are currently 665 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Childrens Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Mucopolysaccharidosis I (MPS I) Registry
NCT00144794
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: Children's Hospital of Wisconsin-Pediatrics- Site Number : 840054, Milwaukee, Wisconsin
Conditions: Mucopolysaccharidosis I (MPS I)
Register for Updates
Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867
Recruiting
This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hepatocellular Carcinoma, Gastric Cancer
Register for Updates
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT03322995
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer
Register for Updates
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT04683315
Recruiting
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreatic Cancer
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Uterine Serous Carcinoma
Register for Updates
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients with Brain Tumors
NCT05023434
Recruiting
The neurosurgical standard of care for treating a patient with a tumor invading hand primary motor cortex (M1) includes performing a craniotomy with intraoperative direct electrical stimulation (DES) mapping and to resect as much tumor as possible without a resultant permanent neurological deficit. However, the subjective nature of current intraoperative hand motor assessments do not offer a comprehensive understanding of how hand strength and function may be impacted by resection. Additionally,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/19/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Brain Tumor, Brain Cancer, Motor Cortex; Lesion
Register for Updates
Abatacept in Immune Checkpoint Inhibitor Myocarditis
NCT05335928
Recruiting
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Aurora St Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Myocarditis Acute, Cancer
Register for Updates
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin +1 locations
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Register for Updates
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
NCT06116110
Recruiting
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Non Hodgkin Lymphoma
Register for Updates
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
NCT06494072
Recruiting
The goal of this open label, randomized, non-inferiority clinical trial is to compare the treatment success of a 5 day antibiotic course versus a standard antibiotic course (usually 7-14 days of antibiotics) in hospitalized children aged 3 months to 18 years, with uncomplicated community acquired pneumonia. The main questions it aims to answer are: * Does a 5 day course work as well as standard (longer) courses of antibiotics for treating community acquired pneumonia in children? * Does a 5 da... Read More
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
11/18/2024
Locations: Childrens Wisconsin, Milwaukee, Wisconsin
Conditions: Community Acquired Pneumonia in Children
Register for Updates
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
NCT06690801
Recruiting
The goal of this observational study is to determine whether a marker of dead space (the end-tidal to alveolar dead space fraction \[AVDSf\]) is more strongly associated with mortality risk than markers of oxygenation abnormality (oxygenation index) and to determine whether dead space (AVDSf) is an important marker of heterogeneity in the inhaled nitric oxide (iNO) treatment effect for children with acute respiratory distress syndrome (ARDS). The study aims are: 1. To validate AVDSf for risk s... Read More
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
11/13/2024
Locations: Children's Hospital of Wisconsin / Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Acute Respiratory Distress Syndrome
Register for Updates
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Recruiting
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma
Register for Updates